Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9

Abstract

Cas9 polypeptides which target RNA and methods of using them are provided.

1 . (canceled) 
     
     
         2 . A pharmaceutical composition comprising:
 an engineered 2-component RNA targeting system comprising:
 (a) a nucleic acid sequence encoding a truncated nuclease-inactive RNA-targeted Cas9 (RCas9) polypeptide, wherein the truncated nuclease-inactive RCas9 polypeptide lacks all or part of its HNH domain compared to the wild-type (WT) Cas9 protein; and 
 (b) a single guide RNA (sgRNA) sequence comprising:
 (i) on its 5′ end, an RNA sequence that hybridizes to or binds to a target RNA sequence comprising a repeat sequence selected from the group consisting of CUG, CCUG, CAG, and GGGGCC; and 
 (ii) on its 3′ end, an RNA sequence capable of binding to or associating with the truncated nuclease-inactive RCas9 polypeptide, wherein the RNA sequence capable of binding to or associating with the truncated nuclease-inactive RCas9 polypeptide comprises or is derived from the wild type guide RNA of an archaeal or a bacterial organism from which the truncated nuclease-inactive RCas9 is derived, 
 
   wherein the RNA targeting system exclusively recognizes and alters the target RNA in the cell in the absence of PAMmers.   
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the truncated nuclease-inactive RCas9 is missing residues 775-909 from full-length Cas9 protein. 
     
     
         4 . The pharmaceutical composition of  claim 2 , wherein the sequences of (a) and (b) are in a single vector. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the sequences of (a) and (b) are a size of less than about 4.5 kb, or a size of less than about 4.7 kb. 
     
     
         6 . The pharmaceutical composition of  claim 2 , wherein the nuclease-inactive RCas9 polypeptide and the RNA sequence capable of binding to or associating with the nuclease-inactive RCas9 polypeptide comprises or is derived from  Haloferax mediteranii, Mycobacterium tuberculosis, Francisella tularensis  subsp.  novicida, Pasteurella multocida, Neisseria meningitidis, Campylobacter jejune, Streptococcus thermophilus, Campylobacterlari, Mycoplasma gallisepticum  str. F,  Nitratifractor salsuginis  str. DSM 16511 , Parvibaculum lavamentivorans, Roseburia intestinalis, Neisseria cinerea, Gluconacetobacter diazotrophicus, Azospirillum  B510 , Sphaerochaeta globus  str. Buddy,  Flavobacterium columnare, Fluviicola taffensis, Bacteroides coprophilus, Mycoplasma mobile, Lactobacillus farciminis, Streptococcus pasteurianus, Lactobacillus johnsonii, Staphylococcus pseudintermedius, Filfactor alocis, Treponema denticola, Legionella pneumophila  str. Paris,  Sutterella wadsworthensis, Corynebacter diphtheriae, Streptococcus aureus , and Natronobacterium gregoryi. 
     
     
         7 . The pharmaceutical composition of  claim 2 , wherein the 5′ end of the sgRNA is between about 15 to 25 nucleotides in length, and wherein the RNA sequence of the RCas9 polypeptide scaffold is between about 85 and 100 nucleotides in length. 
     
     
         8 . The pharmaceutical composition of  claim 2 , wherein the truncated nuclease-inactive RCas9 polypeptide is linked to an effector polypeptide, a targeting agent, an enzyme, a detectable moiety, or a combination thereof. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the effector polypeptide comprises an RNA modifying polypeptide. 
     
     
         10 . The pharmaceutical composition of  claim 8 , wherein the targeting agent comprises:
 (a) a cytoplasmic polyadenylation element binding protein (CPEB), a zinc finger binding protein (ZBP), TIA-1, PSF, the DNA-binding domain (DBD) of PSF, fragile X mental retardation protein (FMRP), IMP1, IMP2, 1MP3, a cytoskeleton binding protein, a transmembrane protein, or   (b) an engineered protein comprising a combination of domains of the proteins of (a).   
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the RNA modifying polypeptide comprises a splicing factor or an RNA splicing domain, a RBFOX2 domain-containing protein, a protein known to influence RNA splicing, an RNA cleaving domain or a PIN domain-containing protein. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the RNA cleaving domain comprises an endonuclease. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the truncated nuclease-inactive RCas9 lacks all of its HNH domain. 
     
     
         14 . The pharmaceutical composition of  claim 2 , wherein the sequence of a) comprises a promoter. 
     
     
         15 . The pharmaceutical composition of  claim 2 , wherein the sequence of b) comprises the U6 polymerase III promoter. 
     
     
         16 . The pharmaceutical composition of  claim 2 , wherein the sequence of b) comprises one or more point mutations that remove the transcription termination sequence. 
     
     
         17 . A pharmaceutical composition comprising:
 an engineered nucleoprotein complex comprising:
 (a) a nuclease-inactive RNA-targeted Cas9 (RCas9) polypeptide, wherein the nuclease-inactive RCas9 polypeptide:
 (i) lacks all or part of an HNH domain, all or part of RuvC nuclease domain, all or part of a Cas9 polypeptide DNase active site, all or part of a ββα-metal fold comprising the Cas9 polypeptide active site, or a combination thereof as compared to the corresponding wild type (WT) Cas9 polypeptide; 
 (ii) lacks DNase, DNA cleaving activity, or nickase activity; and 
 (iii) has a reduced polypeptide size as compared to the corresponding wild type (WT) Cas9 polypeptide that permits packaging of the RCas9-coding nucleotide in a delivery vector; and 
 
 (b) a recombinant or synthetic single guide RNA (sgRNA) comprising:
 (i) on its 5′ end, an RNA sequence that hybridizes to or binds to the target RNA sequence, wherein the target RNA sequence comprises a repeat sequence, wherein the RNA sequence that hybridizes to or binds to the target RNA sequence is capable of hybridizing or binding to the repeat sequence, and wherein the repeat sequence is CUG, CCUG, CAG, GGGGCC, or any combination thereof; and 
 (ii) on its 3′ end:
 (1) an RNA sequence capable of binding to or associating with the nuclease-inactive RCas9 polypeptide, or 
 (2) a linker that covalently links or non-covalently links the 5′ RNA sequence of the sgRNA with the nuclease-inactive RCas9 polypeptide, 
 
 
 wherein the engineered nucleoprotein complex recognizes and alters target RNA in the cell in the absence of a PAMmer. 
   
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein the nuclease-inactive RCas9 polypeptide is covalently linked to an effector polypeptide, a detectable moiety, or an RNA modifying polypeptide. 
     
     
         19 . The pharmaceutical composition of  claim 17 , wherein said RNA modifying polypeptide comprises a splicing factor or an RNA splicing domain, a RBFOX2 domain-containing protein, an RNA cleaving domain or a PIN domain-containing protein. 
     
     
         20 . The pharmaceutical composition of  claim 17 , wherein said sgRNA comprises one or more point mutations that remove the transcription termination sequence or a portion thereof. 
     
     
         21 . The pharmaceutical composition of  claim 17 , wherein said sgRNA comprises one or more of methylphosphonate, thiophosponoaceteate, and phosphorothioate linkages that reduce nuclease activity on the target RNA.